Pfizer Inc. (NYSE:PFE) Shares Bought by Loudon Investment Management LLC

Loudon Investment Management LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 26,580 shares of the biopharmaceutical company’s stock after buying an additional 1,028 shares during the period. Loudon Investment Management LLC’s holdings in Pfizer were worth $765,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Briaud Financial Planning Inc acquired a new position in shares of Pfizer in the 3rd quarter valued at $30,000. Mizuho Securities Co. Ltd. acquired a new position in shares of Pfizer in the 3rd quarter valued at $34,000. VisionPoint Advisory Group LLC lifted its stake in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the last quarter. GoalVest Advisory LLC lifted its stake in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new position in shares of Pfizer in the 4th quarter valued at $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on PFE. Guggenheim began coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a report on Thursday. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Eleven investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $36.00.

Pfizer Stock Performance

Shares of PFE stock traded up $0.52 during trading hours on Thursday, reaching $27.70. 63,855,289 shares of the company’s stock were exchanged, compared to its average volume of 42,875,957. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $40.37. The company has a market cap of $156.85 billion, a P/E ratio of 77.25, a price-to-earnings-growth ratio of 1.15 and a beta of 0.63. The company’s 50 day moving average is $26.87 and its two-hundred day moving average is $28.25. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. During the same period last year, the business posted $1.23 EPS. Pfizer’s quarterly revenue was down 19.5% on a year-over-year basis. Equities research analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.06%. The ex-dividend date is Thursday, May 9th. Pfizer’s payout ratio is currently 466.67%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.